Cardiovascular Systems Inc. (NASDAQ:CSII) Director Edward M. Brown sold 10,000 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $26.78, for a total transaction of $267,800.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Cardiovascular Systems Inc. (NASDAQ:CSII) opened at 26.39 on Tuesday. The stock’s market cap is $872.53 million. Cardiovascular Systems Inc. has a 12 month low of $7.50 and a 12 month high of $27.38. The stock has a 50 day moving average of $24.20 and a 200 day moving average of $21.04.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, October 26th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.13. Cardiovascular Systems had a negative net margin of 24.24% and a negative return on equity of 30.19%. The firm earned $49.80 million during the quarter, compared to analysts’ expectations of $205.50 million. During the same period last year, the business earned ($0.41) earnings per share. Cardiovascular Systems’s revenue was up 13.5% compared to the same quarter last year. On average, equities analysts anticipate that Cardiovascular Systems Inc. will post ($0.21) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, August 8th. Needham & Company LLC boosted their price objective on shares of Cardiovascular Systems from $23.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, August 4th. Leerink Swann reissued an “outperform” rating and issued a $30.00 price objective on shares of Cardiovascular Systems in a research report on Tuesday, November 15th. Feltl & Co. raised shares of Cardiovascular Systems from a “buy” rating to a “strong-buy” rating and set a $30.00 price objective for the company in a research report on Thursday, October 27th. Finally, Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research report on Thursday, August 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $27.50.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in shares of Cardiovascular Systems by 27.6% in the first quarter. Wellington Management Group LLP now owns 3,018,859 shares of the medical device company’s stock worth $31,306,000 after buying an additional 652,962 shares during the period. Iguana Healthcare Management LLC acquired a new position in shares of Cardiovascular Systems during the first quarter worth $754,000. Cutler Group LP boosted its position in shares of Cardiovascular Systems by 4.7% in the second quarter. Cutler Group LP now owns 7,787 shares of the medical device company’s stock worth $143,000 after buying an additional 350 shares during the period. Perkins Capital Management Inc. boosted its position in shares of Cardiovascular Systems by 17.8% in the second quarter. Perkins Capital Management Inc. now owns 111,600 shares of the medical device company’s stock worth $2,051,000 after buying an additional 16,900 shares during the period. Finally, Strs Ohio acquired a new position in shares of Cardiovascular Systems during the second quarter worth $194,000. Hedge funds and other institutional investors own 69.77% of the company’s stock.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.